This content is in French.
Alzheimer’s in a drop of blood?
21 septembre 2025
By Ana Espino | Published on september 21, 2025 | 3 min read
#Alzheimer #Tau #Neurology
Alzheimer’s disease is a progressive neurodegenerative disorder, responsible for irreversible cognitive decline and loss of autonomy, associated with the abnormal accumulation of beta-amyloid and phosphorylated tau in the brain. It is the leading cause of dementia worldwide. Diagnosis still relies heavily on invasive and costly tools: cerebrospinal fluid (CSF) biomarkers, brain imaging (amyloid or tau PET), and complex clinical assessments, which are often difficult to access in everyday practice. These limitations hinder early screening and the implementation of targeted therapeutic strategies, particularly in the silent stages of the disease.
#Alzheimer #Tau #Neurology
Alzheimer’s disease is a progressive neurodegenerative disorder, responsible for irreversible cognitive decline and loss of autonomy, associated with the abnormal accumulation of beta-amyloid and phosphorylated tau in the brain. It is the leading cause of dementia worldwide. Diagnosis still relies heavily on invasive and costly tools: cerebrospinal fluid (CSF) biomarkers, brain imaging (amyloid or tau PET), and complex clinical assessments, which are often difficult to access in everyday practice. These limitations hinder early screening and the implementation of targeted therapeutic strategies, particularly in the silent stages of the disease.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Therriault, J., et al. (2025). Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. The Lancet Neurology, 24(9), 740-752
View the source
